Baidu
map

IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验:首位患者已入组

2020-07-27 Allan MedSci原创

IMU-838已成功证明了其对重症急性呼吸综合征冠状病毒2(SARS-CoV-2)的临床前活性。

Immunic是一家临床阶段的生物制药公司,Immunic今日宣布已开始选择性口服DHODH抑制剂IMU-838联合神经氨酸酶抑制剂Oseltamivir(Tamiflu)治疗中重度COVID-19的II期临床试验(ONIC试验)。ONIC试验是一项前瞻性、随机、平行分组、开放标签的IIb期研究。

IMU-838已成功证明了其对重症急性呼吸综合征冠状病毒2(SARS-CoV-2)的临床前活性。IMU-838能够抑制SARS-CoV-2病毒的复制。此外,IMU-838的药代动力学、安全性和耐受性均良好。

英国胃肠病学会主席Ramesh Arasaradnam教授评论说:“最新的研究强调,临床前模型显示抗病毒药物和DHODH抑制剂之间的强大协同作用。我们相信,在英国已获许可的药物Oseltamivir与IMU-838的结合可能提供了一种有前途的方法用于治疗严重的病毒感染,包括中晚期COVID-19患者”。

二氢乳清酸脱氢酶(DHODH)是由人类16号染色体上的DHODH基因编码的酶。由该基因编码的酶在嘧啶的从头合成(de novo synthesis)中催化第四步酶促步骤,即泛醌介导的二氢乳清酸氧化为乳清酸。该蛋白是位于线粒体内膜(IMM)外表面的线粒体蛋白。

 

原始出处:

https://www.firstwordpharma.com/node/1743602?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038339, encodeId=cb5e203833916, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Thu Nov 19 12:14:07 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931520, encodeId=5307193152017, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Dec 10 22:14:07 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088815, encodeId=6756208881580, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Nov 27 11:14:07 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653061, encodeId=b6df165306160, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 01 16:14:07 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806333, encodeId=6386806333be, content=期待期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:52:54 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524842, encodeId=89401524842a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jul 29 12:14:07 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804802, encodeId=82ac804802c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:22 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038339, encodeId=cb5e203833916, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Thu Nov 19 12:14:07 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931520, encodeId=5307193152017, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Dec 10 22:14:07 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088815, encodeId=6756208881580, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Nov 27 11:14:07 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653061, encodeId=b6df165306160, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 01 16:14:07 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806333, encodeId=6386806333be, content=期待期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:52:54 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524842, encodeId=89401524842a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jul 29 12:14:07 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804802, encodeId=82ac804802c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:22 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038339, encodeId=cb5e203833916, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Thu Nov 19 12:14:07 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931520, encodeId=5307193152017, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Dec 10 22:14:07 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088815, encodeId=6756208881580, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Nov 27 11:14:07 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653061, encodeId=b6df165306160, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 01 16:14:07 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806333, encodeId=6386806333be, content=期待期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:52:54 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524842, encodeId=89401524842a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jul 29 12:14:07 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804802, encodeId=82ac804802c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:22 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038339, encodeId=cb5e203833916, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Thu Nov 19 12:14:07 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931520, encodeId=5307193152017, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Dec 10 22:14:07 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088815, encodeId=6756208881580, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Nov 27 11:14:07 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653061, encodeId=b6df165306160, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 01 16:14:07 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806333, encodeId=6386806333be, content=期待期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:52:54 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524842, encodeId=89401524842a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jul 29 12:14:07 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804802, encodeId=82ac804802c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:22 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038339, encodeId=cb5e203833916, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Thu Nov 19 12:14:07 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931520, encodeId=5307193152017, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Dec 10 22:14:07 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088815, encodeId=6756208881580, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Nov 27 11:14:07 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653061, encodeId=b6df165306160, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 01 16:14:07 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806333, encodeId=6386806333be, content=期待期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:52:54 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524842, encodeId=89401524842a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jul 29 12:14:07 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804802, encodeId=82ac804802c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:22 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2020-08-05 武亚晶

    期待期待

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2038339, encodeId=cb5e203833916, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Thu Nov 19 12:14:07 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931520, encodeId=5307193152017, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Dec 10 22:14:07 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088815, encodeId=6756208881580, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Nov 27 11:14:07 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653061, encodeId=b6df165306160, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 01 16:14:07 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806333, encodeId=6386806333be, content=期待期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:52:54 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524842, encodeId=89401524842a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jul 29 12:14:07 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804802, encodeId=82ac804802c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:22 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2038339, encodeId=cb5e203833916, content=<a href='/topic/show?id=77dc10129e89' target=_blank style='color:#2F92EE;'>#首位患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101297, encryptionId=77dc10129e89, topicName=首位患者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Thu Nov 19 12:14:07 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931520, encodeId=5307193152017, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Dec 10 22:14:07 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088815, encodeId=6756208881580, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Nov 27 11:14:07 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653061, encodeId=b6df165306160, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 01 16:14:07 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806333, encodeId=6386806333be, content=期待期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:52:54 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524842, encodeId=89401524842a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jul 29 12:14:07 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804802, encodeId=82ac804802c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:22 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2020-07-27 ms6487490578077260

    期待

    0

相关资讯

细胞疗法PneumoBlast™可减少COVID-19肺纤维化的形成

制药公司FibroGenesis今日宣布,在肺部纤维化模型中,其细胞疗法PneumoBlast™可减少51%的肺纤维化。更为重要的是,与骨髓来源的间充质干细胞(BMSC)相比,Pneumo

Braz J Otorhinolaryngol:嗅觉丧失与COVID-19关系紧密

由于一些国家的实验室测试能力有限,COVID-19案例的真实数量可能被低估。因此,发现一个具有高的预测价值的症状在诊断和隔离策略中是非常有帮助的。

medRxiv:警惕!日本研究发现,清肺排毒汤会导致促炎细胞因子水平上调!

导言:在没有有效的新冠肺炎疫苗的情况下,中医药开辟蹊径,取得阶段性进展。而中药中一位“猛将”,清肺排毒汤,也因在山西等4个省份试点后明确指出总有效率达90%以上而闻名。近日,日

NEJM:正式发表!大规模随机对照试验,廉价药地塞米松可以降低新冠患者(有创通气)30%以上的死亡率

由于新病例的迅速增加,2019年冠状病毒病(COVID-19)很快引起了全球关注,病原体被鉴定为SARS-CoV-2。截至目前(7月18日),据约翰·霍普金斯大学发布的实时统计数据,全球

COVID-19候选疫苗mRNA-1273的III临床试验:规模将继续扩大

临床阶段生物技术公司Moderna是信使RNA(mRNA)治疗剂和疫苗的先驱,Moderna今日宣布对BARDA(生物医学高级研究与开发管理局)追加高达4.72亿美元的额外投资,以支持后期临床开发。

Sci Immun:IFN-1有望成为治疗重症新冠肺炎的“靶点新星”

据美国有线电视新闻网(CNN)7月11日报道,美国疾病控制与预防中心更新了针对公共卫生官员和数学建模研究员的指南。该指南估计,“40%的新冠病毒(SARS-CoV-2)感染者没有症状&rd

拓展阅读

Epidemiology and Psychiatric Sciences:疫情期间青少年和年轻人抗抑郁药物使用激增的时间序列分析洞察

COVID-19疫情期间,青少年和年轻人抗抑郁药物使用显著增加,特别是女性和非意大利籍青少年增幅尤为突出,提示心理健康需求可能在疫情后持续增加。

Int Forum Allergy Rhinol:嗅觉训练与年龄有关的差异

美国科学家发现,50岁以下的年轻患者和50岁以上的年长患者在接受OT治疗后,嗅觉功能都有类似的明显改善。但两组患者的主观改善时间不同,年轻患者的改善时间更早。

如何设定重症患者和手术室中的初始呼吸频率?对使用机械通气的 COVID-19 患者的初始设置的影响。

讨论机械通气患者呼吸频率设置,不同患者情况不同,重症患者常需较高呼吸频率,对 COVID-19 患者也给出相应设置建议。

无创正压通气中的头盔

介绍新冠大流行使头盔作为输送呼气末正压等的接口受关注。阐述头盔通气设置、临床证据等,表明其在急性呼吸衰竭中安全且可能有优势,但需准确选择患者和密切监测。

European Child & Adolescent Psychiatry:COVID-19大流行对门诊饮食失调管理流行率和神经性厌食症严重程度的影响

本研究发现COVID-19大流行期间,女孩的饮食失调症流行率显著增加,但住院患者的病情严重程度未见显著变化。这提示大流行期间,门诊服务需求显著增加。

JAMA子刊:COVID-19疫苗接种对儿童哮喘的影响

研究发现更高的COVID-19疫苗接种率可能对症状性哮喘有保护作用。

Baidu
map
Baidu
map
Baidu
map